India vs China Peptide API Sourcing for US Buyers

Choose the peptide API supplier, in India or China, that clears six evidence checks: site identity, GMP status, filing support, batch quality, supply-chain visibility, and continuity planning. Country of origin is a sourcing input, not proof that a specific peptide, facility, or shipment fits a US program.

Use the same qualification request for every supplier. Then compare the evidence with QA, CMC, regulatory affairs, and logistics before you place a commercial order.

Use This India-Versus-China Decision Table First

Send this table with your RFQ to every shortlisted supplier. It gives India and China suppliers the same test.

A supplier that cannot complete a row has not yet earned a US commercial commitment. A lower quote does not close an evidence gap.

Start with the Product and Intended US Use

Define the exact peptide, salt or counterion, dosage-form use, annual demand, program stage, and required US filing pathway before comparing countries. A clinical API, a commercial drug-substance source, and a research material require different documentation packages.

Foreign establishments that manufacture API for US import generally must register with FDA and list commercially distributed APIs. FDA also expects the foreign establishment to identify known importers in its registration. Read FDA’s API import rules before writing the RFQ.

Ask each supplier these six opening questions:

1. What legal entity manufactures this exact peptide?
2. Which site performs synthesis, purification, testing, packaging, and release?
3. What specification and analytical methods apply to the proposed lot?
4. Does a Type II DMF exist for this exact peptide, and can you provide a Letter of Authorization?
5. Which critical materials and manufacturers support the process?
6. What packaging and shipping lane support the proposed US delivery?

At Aarise Pharma, we supply peptide APIs from India to pharmaceutical buyers and support custom synthesis for proprietary sequences. Our peptide range includes peptide raw materials for US sourcing, with product-specific documentation discussed during the sourcing process. See our US peptide sourcing guide when preparing an RFQ.

Check GMP Evidence at the Actual Site

A GMP certificate only helps when it covers the actual operation that makes your peptide. Match the certificate, audit scope, site address, and production role against the supplier’s batch records and quality agreement.

FDA’s inspection database uses three final classifications. No Action Indicated means FDA found an acceptable state of compliance. Voluntary Action Indicated means FDA found objectionable conditions but did not recommend action. Official Action Indicated means FDA found an unacceptable state of compliance. Use the FDA inspection database for a public check.

Also search the named site in Import Alert 66-40. That alert covers drug firms that FDA believes have not met drug GMP requirements and may face detention without physical examination.

Ask the supplier for:

• The manufacturing address and FDA Establishment Identifier, if one exists.
• The latest GMP certificate and its scope.
• The latest inspection classification or inspection-response package.
• A current quality-system summary.
• A signed quality agreement before commercial supply.

FDA recommends quality agreements that clearly assign manufacturing, deviation, communication, and release responsibilities between the product owner and contract facility. Read the FDA quality-agreement guidance.

Treat DMF Support as Filing Support, Not Approval

A Type II Drug Master File, or DMF, can hold confidential information about a drug substance, its manufacturing process, or materials used in preparation. It can support an IND, NDA, ANDA, or another submission when the holder authorizes FDA to reference it.

A DMF is not FDA approval. FDA states that DMFs are neither approved nor disapproved, and FDA reviews their technical contents only with a referenced application. See FDA’s DMF overview.

For each supplier, ask for the exact peptide name, DMF holder, DMF subject, active status, and Letter of Authorization process. Regulatory affairs should decide whether that package fits your program.

For an approved product, a drug-substance manufacturing-site change can trigger FDA reporting or prior-approval requirements. FDA’s postapproval change guidance explains why second-source work belongs in the regulatory plan early.

Map the Peptide Supply Chain Beyond the API Site

A peptide API supplier may control synthesis while relying on other manufacturers for protected amino acids, resins, coupling reagents, linkers, solvents, or intermediates. Your supply-chain map should name the critical material, its actual manufacturer, qualified alternate source, and change-control process.

ICH Q7 states that API manufacturers should evaluate suppliers of critical materials. It also says the API manufacturer should know the critical material’s actual manufacturer when that company differs from the supplier. A change to a critical raw-material source belongs in change control. See ICH Q7 materials controls.

Ask for a one-page critical-material map. It should identify:

• Critical starting materials and reagents.
• Actual manufacturers, not only distributors.
• Approved-source status.
• Incoming testing and release controls.
• Change-notification responsibilities.
• Alternate-source feasibility.

Our peptide API supply-chain qualification checklist helps buyers turn that request into a supplier-review file.

Review the Batch Package Before You Compare Price

A COA proves only what the document reports for its named lot. Review the lot number, specification version, analytical method, result, date, release signature, and sample relationship together.

For a peptide API, the agreed package may include identity confirmation, purity, assay or content, related substances, residual solvents, water, microbial controls, endotoxin where relevant, and stability or retest support. The exact package should match the intended dosage form and program requirements.

Do not treat HPLC purity and peptide content as the same result. HPLC purity measures the proportion of chromatographic material under a defined method. Content or assay measures the amount of the intended material against a standard. Use our guide to HPLC purity versus peptide content when setting the release specification.

Require an independent investigation before accepting a lot with an unmatched COA, unexplained method change, missing chromatogram, or conflicting identity result.

Approve the Shipping Lane, Not Just the Freight Quote

Ask for the proposed Incoterm, importer-of-record responsibilities, package configuration, lane, carrier, storage limits, temperature logger, and excursion procedure. “Cold chain” is not enough. The supplier must show that the proposed package and route protect the exact peptide.

ICH stability guidance defines specifications as the tests and acceptance criteria that establish a drug substance’s suitability through its retest period. It also requires assessment of stability excursions that could affect the material. Read ICH Q1A(R2).

The release decision after a temperature excursion should name the responsible quality unit. The quality unit should review the logger data against product-specific stability evidence before releasing the shipment for use.

A country comparison belongs here as a continuity question. Compare each supplier’s export route, port or airport options, upstream dependencies, and backup production plan. Do not assume that an Indian supplier lacks China exposure, or that a Chinese supplier lacks alternative options. The supply-chain map answers that question.

Qualify a Second Source Before a Disruption

Begin second-source qualification when a program relies on one manufacturing site, one critical-material maker, one untested logistics lane, or one supplier without reserved capacity. Begin it when a supplier cannot support the needed filing path.

A second source needs more than a second quotation. It needs comparable technical evidence, a batch package, quality agreement, supply-chain map, shipping plan, and a regulatory assessment.

ICH Q9 recommends risk-based oversight of external suppliers throughout the product lifecycle. It also recognizes that a pre-qualified alternative may be necessary when supply-chain performance becomes unreliable. Read ICH Q9 risk management.

For approved products, have regulatory affairs assess the source change before ordering qualification batches. FDA may require a supplement before certain manufacturing changes take effect.

FAQs

Can One Supplier Use Another Company’s DMF?

Yes, if the DMF holder authorizes FDA to reference the file for the relevant application. The supplier should provide the Letter of Authorization process and identify the exact DMF subject. A DMF holder’s authorization does not make the API approved on its own. See FDA’s DMF guidance.

Should the Same Checklist Apply to Clinical and Commercial Supply?

Yes, use the same six evidence areas for both. Commercial supply usually needs a deeper capacity, change-control, filing, and continuity review because a disruption affects ongoing product availability. Set the evidence depth around your program’s stage and intended US use.

What Should a Quality Agreement Say About a Temperature Excursion?

The quality agreement should name who receives the alert, who reviews logger data, who investigates the excursion, and who makes the final disposition decision. FDA expects quality agreements to assign responsibilities clearly between product owners and contract facilities. Use the FDA agreement guidance when setting those roles.

Can a US Buyer Change Peptide API Sites After Approval?

Yes, but the change may require FDA reporting or prior approval. The required pathway depends on the approved application and the nature of the site and process change. Regulatory affairs should assess the change before the new site supplies commercial material.

Aarise Pharma can provide an India-source peptide API RFQ pathway for pharmaceutical buyers who need product-specific quality, documentation, and shipping discussions. Start with our peptide and hormone API buyer’s guide and request the evidence package for your exact molecule.